WO2004003166A3 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof Download PDF

Info

Publication number
WO2004003166A3
WO2004003166A3 PCT/US2003/020602 US0320602W WO2004003166A3 WO 2004003166 A3 WO2004003166 A3 WO 2004003166A3 US 0320602 W US0320602 W US 0320602W WO 2004003166 A3 WO2004003166 A3 WO 2004003166A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
metastasis
fragments
present
methods
Prior art date
Application number
PCT/US2003/020602
Other languages
French (fr)
Other versions
WO2004003166A2 (en
Inventor
Avigdor Levanon
Rachel Ben-Levy
Daniel Plaksin
Esther Szanton
Yocheved Hagai
Mar-Chaim Hagit Hoch
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Priority to AU2003263764A priority Critical patent/AU2003263764A1/en
Priority to MXPA05000272A priority patent/MXPA05000272A/en
Priority to JP2004518132A priority patent/JP2005536199A/en
Priority to BR0312483-5A priority patent/BR0312483A/en
Priority to CA002491363A priority patent/CA2491363A1/en
Priority to EP03762258A priority patent/EP1534332A4/en
Publication of WO2004003166A2 publication Critical patent/WO2004003166A2/en
Priority to IL16606304A priority patent/IL166063A0/en
Publication of WO2004003166A3 publication Critical patent/WO2004003166A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)

Abstract

The present invention provides antibodies or fragments thereof that bind to cancer cells and are important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic, prognostic or staging methods and compositions using such antibodies or fragments thereof are also provided. The methods and compositions according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, autoimmune disease, and inflammatory disease.
PCT/US2003/020602 2002-07-01 2003-06-30 Antibodies and uses thereof WO2004003166A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2003263764A AU2003263764A1 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof
MXPA05000272A MXPA05000272A (en) 2002-07-01 2003-06-30 Antibodies and uses thereof.
JP2004518132A JP2005536199A (en) 2002-07-01 2003-06-30 Antibodies and their use
BR0312483-5A BR0312483A (en) 2002-07-01 2003-06-30 Antibodies and their uses
CA002491363A CA2491363A1 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof
EP03762258A EP1534332A4 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof
IL16606304A IL166063A0 (en) 2002-07-01 2004-12-30 Antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903202A 2002-07-01 2002-07-01
US10/189,032 2002-07-01

Publications (2)

Publication Number Publication Date
WO2004003166A2 WO2004003166A2 (en) 2004-01-08
WO2004003166A3 true WO2004003166A3 (en) 2005-03-10

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020602 WO2004003166A2 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof

Country Status (12)

Country Link
EP (1) EP1534332A4 (en)
JP (1) JP2005536199A (en)
KR (1) KR20060011925A (en)
CN (1) CN1678347A (en)
AU (1) AU2003263764A1 (en)
BR (1) BR0312483A (en)
CA (1) CA2491363A1 (en)
IL (1) IL166063A0 (en)
MX (1) MXPA05000272A (en)
PL (1) PL374439A1 (en)
RU (1) RU2005101621A (en)
WO (1) WO2004003166A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (en) 2003-09-05 2005-03-06 Gentium Spa FORMATIONS FOR ANTITUMORAL ACTION.
TWI454275B (en) 2004-05-11 2014-10-01 Abgenomics Cooperatief Ua T-cell death-inducing epitopes
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
US8980862B2 (en) 2010-11-12 2015-03-17 Gentium S.P.A. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD)
RU2650817C2 (en) 2011-06-13 2018-04-17 Абгеномикс Кооператиф У.А. Anti-psgl-1-antibodies and their application
CN110079580B (en) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
KR101896751B1 (en) * 2015-12-01 2018-10-04 주식회사 엘지화학 Thermoplastic resin, method for preparing the resin and thermoplastic resin composition comprising the resin
US20230243836A1 (en) * 2018-07-20 2023-08-03 Pierre Fabre Medicament Receptor for vista
CN111715409B (en) * 2020-07-01 2021-07-23 中南大学 Combined lead inhibitor of micro-fine particle galena and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1342085A (en) * 1998-10-30 2002-03-27 遗传研究所有限公司 Inhibition of differentiation of cytotoxic T-cells by p-selecting ligand (PSGL) antagonists
PL362227A1 (en) * 2000-03-24 2004-10-18 Genetic Institute, Llc A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRENETTE P.S.: "P-selection glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo", J. EXP. MED., vol. 191, no. 8, 17 April 2000 (2000-04-17), pages 1413 - 1422, XP002983422 *

Also Published As

Publication number Publication date
AU2003263764A1 (en) 2004-01-19
BR0312483A (en) 2005-08-09
EP1534332A4 (en) 2006-11-22
MXPA05000272A (en) 2005-09-20
WO2004003166A2 (en) 2004-01-08
RU2005101621A (en) 2005-11-20
KR20060011925A (en) 2006-02-06
CA2491363A1 (en) 2004-01-08
IL166063A0 (en) 2006-01-15
JP2005536199A (en) 2005-12-02
CN1678347A (en) 2005-10-05
PL374439A1 (en) 2005-10-17
EP1534332A2 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2004003166A3 (en) Antibodies and uses thereof
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004518132

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047021603

Country of ref document: KR

Ref document number: 2491363

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 374439

Country of ref document: PL

Ref document number: PA/a/2005/000272

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200500245

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003263764

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 175/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003762258

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 537918

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2005101621

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 20038204029

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003762258

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047021603

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2003762258

Country of ref document: EP